01—Abstract
Summary
Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported third quarter 2024 results on October 30, 2024, per Exhibit 99.1 to this Form 8-K.
Third quarter total revenues were $622.1 milliona, versus $498.8 million in the third quarter of 2023, with net product sales of $616.6 million. INGREZZA third quarter net product sales were $613 million, growing 26% year over year, driven by underlying patient demand and improved gross-to-net dynamics. GAAP net income was $129.8 million, or $1.24 per diluted share, compared with $83.1 million, or $0.82, a year earlier.
Non-GAAP net income was $189.2 millionb, or $1.81 per diluted share. Cash, cash equivalents and marketable securities totaled $1,871.9 million at September 30, 2024. The company raised its 2024 INGREZZA net product sales guidance to $2.30 to $2.32 billion and updated its expense guidance.
GAAP R&D is now expected at $700 to $720 millionc and GAAP SG&A at $970 to $990 million. Management cited investments in R&D, the expanded psychiatry and long-term care sales teams, and pre-launch activities for crinecerfont, which has a Priority Review from the FDA in congenital adrenal hyperplasia. The Board authorized a $300 million share repurchase plan, and the company intends to enter a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions.
The filing also discloses pipeline and leadership developments. Kyle W. Gano, Ph.D. became Chief Executive Officer effective October 11, 2024.
The Phase 2 study of NBI-1117568, an M4 agonist for schizophrenia, was positive and triggered a $35 milliond milestone payment to Nxera, with Phase 3 initiation expected in the first half of 2025. The luvadaxistat Phase 2 ERUDITE study missed its primary endpoint, and the company has given notice to terminate that license with Takeda, effective April 2025.
02—Key points
Key Highlights
- Third quarter 2024 total revenues of $622.1 million, up from $498.8 million in the third quarter of 2023.
- INGREZZA third quarter net product sales of $613 million, up 26% year over year.
- GAAP diluted EPS of $1.24 versus $0.82 a year earlier; non-GAAP diluted EPS of $1.81 versus $1.54.
- 2024 INGREZZA net product sales guidance raised to $2.30 to $2.32 billion.
- Board authorized a $300 million share repurchase plan, to be executed as an accelerated share repurchase transaction.
- Cash, cash equivalents and marketable securities of $1,871.9 million at September 30, 2024, up from $1,719.1 million at December 31, 2023.
- Pipeline update: positive Phase 2 data for NBI-1117568 in schizophrenia; luvadaxistat Phase 2 ERUDITE study missed its primary endpoint, and the Takeda license is being terminated.
03—Questions
Frequently Asked Questions
How did INGREZZA perform in the third quarter of 2024?
INGREZZA third quarter 2024 net product sales were $613 million, growing 26% compared with the third quarter of 2023. The company attributed the growth to strong underlying patient demand and improved gross-to-net dynamics.
What changed in the company's 2024 guidance?
INGREZZA net product sales guidance was raised to $2.30 to $2.32 billion. GAAP R&D expense guidance is $700 to $720 million, and GAAP SG&A expense guidance is $970 to $990 million. Non-GAAP guidance excludes items such as stock-based compensation, vacated legacy campus facility costs, and a roughly $15 million fourth-quarter charge tied to the CEO's retirement.
What is the share repurchase plan?
The Board authorized a $300 million share repurchase plan. The company intends to enter a $300 million accelerated share repurchase transaction in the coming days, subject to market conditions, which will constitute the entirety of the authorized plan.
What pipeline developments were reported?
NBI-1117568 showed positive topline Phase 2 results in schizophrenia, triggering a $35 million milestone payment to Nxera, with Phase 3 expected to start in the first half of 2025. The ERUDITE Phase 2 study of luvadaxistat in cognitive impairment associated with schizophrenia did not meet its primary endpoint, and the Takeda license is being terminated effective April 2025. The Idorsia license for NBI-827104 is also being terminated, effective January 2025.
Who is the company's leadership and what changed?
Kyle W. Gano, Ph.D. was appointed Chief Executive Officer effective October 11, 2024. The filing notes the retirement of the prior CEO in October 2024, which is associated with an approximate $15 million stock-based compensation charge in the fourth quarter.
04—Continue